Source: PR Newswire

Press Release: Schrodinger : Schrödinger and Tri-Institutional Therapeutics Discovery Institute Renew Agreement to Provide Drug Discovery Software to Tri-Institutional Researchers

NEW YORK, April 12, 2018 /PRNewswire/ -- Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, and the Tri-Institutional Therapeutics Discovery Institute, Inc. (TRI-I TDI) have renewed and extended, for an additional...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Ramy Farid's photo - President & CEO of Schrodinger

President & CEO

Ramy Farid

CEO Approval Rating


Schrodinger develops a chemical simulation software that offers drug design and molecular modeling solutions for pharmaceutical and biotechnology companies. Read more